论文部分内容阅读
有乙型肝炎病毒(HBV)感染史的患者在接受化疗或者免疫抑制剂治疗后,可能HBV会复活。而HBV的再次激将会引起严重后果甚至可能致命。不过这可能只是冰山一角。这篇review文章发表在近期的Hepatology杂志上。乙型肝炎由体液接触传播,导致急性或慢性肝炎。接种疫苗有助于控制乙肝病毒的传播。医学统计估计,全球人口有10%感染有慢性HBV。美国食品和药物管理局(FDA)曾于2013年9月签署了一份药物安全沟通书,表示警告免疫抑制和抗癌药物奥法木单抗(Arzerra ofatumumab)和
Patients with a history of hepatitis B virus infection may be revived after receiving chemotherapy or immunosuppressive therapy. The re-shock of HBV will cause serious consequences and may even be fatal. But this may be just the tip of the iceberg. This review article was published in the recent Hepatology Journal. Hepatitis B is transmitted by body fluids and causes acute or chronic hepatitis. Vaccination helps control the spread of hepatitis B virus. Medical statistics estimate that 10% of the global population is infected with chronic HBV. The U.S. Food and Drug Administration (FDA) signed a drug safety communications book in September 2013, warning that the immunosuppressive and anti-cancer drug Arzerra ofatumumab and